Cooley’s 2024 Life Sciences M&A Year in Review: M&A Slims Down in 2024, but Will Appetites Grow in 2025?
Cooley M&A
JANUARY 22, 2025
This approach, combining M&A and initial public offering (IPO) preparations on parallel tracks, allows companies to maximize optionality in an uncertain market. Looking forward, we expect a focus on the sector by the FTC to continue, especially given that perceived high drug prices remain a bipartisan area of concern.
64 
Let's personalize your content